Drug Discovery Informatics Market to 2031 - Growth and Trends
[Research Report] The drug discovery informatics market was valued at US$ 3.07 billion in 2023 and is expected to reach US$ 8.17 billion by 2031; it is estimated to record a CAGR of 13.0% during 2023–2031.
Market Insights and Analyst View:
The drug discovery informatics market forecast is derived on the basis of findings from various secondary and primary research sources.
Drug discovery informatics is a field that integrates computational and information sciences with chemistry and biology. It uses various computational tools, algorithms, and databases to study and interpret vast volumes of biological and chemical data. By utilizing the power of informatics, researchers can speed up the drug discovery process, resulting in the identification of potential drug candidates more efficiently and cost-effectively. Thus, the adoption of informatics tools is contributing to the growing drug discovery informatics market size.
Drivers Affecting Drug Discovery Informatics Market Growth
Pharmaceutical and biopharmaceutical industries invest heavily in R&D to develop new products and expand product pipelines in areas such as immunology, cancer, and infectious diseases. For instance, many innovative pharmaceutical companies are now investing in genomics to re-energize drug discovery. According to the article published by the Journal of Precision Medicine in March 2021, AstraZeneca launched a project to sequence 2 million genomes—a massive initiative aimed at collecting genome sequences and health records over the next decade. The same source further stated that GlaxoSmithKline invested £40 (UD$ 42.48) million to expand its partnership with the UK Biobank. This investment supports the sequencing of 500,000 individuals, generating a uniquely rich data resource that is both anonymized and secure. Instead of sourcing data, the leading pharmaceutical companies are tapping into population data sets that are rich in genomic, phenotypic, and clinical data. Therefore, the increasing investments in activities focused on drug discovery are driving the drug discovery informatics market growth.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Drug Discovery Informatics Market: Strategic Insights
Market Size Value in US$ 3.07 billion in 2023 Market Size Value by US$ 8.17 billion by 2031 Growth rate CAGR of 13.0% from 2023 to 2031 Forecast Period 2023-2031 Base Year 2023
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Drug Discovery Informatics Market: Strategic Insights
| Market Size Value in | US$ 3.07 billion in 2023 |
| Market Size Value by | US$ 8.17 billion by 2031 |
| Growth rate | CAGR of 13.0% from 2023 to 2031 |
| Forecast Period | 2023-2031 |
| Base Year | 2023 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Report Segmentation and Scope:
The "Global Drug Discovery Informatics Market Analysis to 2031" is a specialized and in-depth study focusing on the global market dynamics to help identify the key driving factors, future trends, and lucrative opportunities that would, in turn, aid in identifying major revenue pockets. The report aims to provide an overview of the market with detailed market segmentation by workflow, services, solutions, and end user. The scope of the drug discovery informatics market report entails North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
Segmental Analysis:
By workflow, the market is bifurcated into discovery informatics and drug development. The discovery informatics segment held a larger market share in 2023. The drug development segment is projected to register a higher CAGR from 2023 to 2031.
The market, by service, is segmented into sequence analysis platforms, molecular modeling, clinical trial data management, docking, and others. The sequence analysis platform segment is anticipated to hold the largest drug discovery informatics market share in 2023. The molecular modeling segment is projected to register the highest CAGR from 2023 to 2031.
By solution, the drug discovery informatics market is segmented into software and services. The services segment held a larger market share in 2023, and the same segment is projected to register a higher CAGR from 2023 to 2031.
Based on end user, the market is segmented into pharmaceutical and biotechnology companies, contract research organizations, and others. The pharmaceutical and biotechnology companies segment held the largest share of the market in 2023. The contract research organizations segment is expected to register the highest CAGR from 2023 to 2031.
Regional Outlook:
North America held the largest drug discovery informatics market share in 2023. The US held the largest share of the market in 2023, followed by Canada. This is attributed to factors such as the presence of major players, including Charles River Laboratories, Certara, and Curia, the high incidence of infectious diseases, and the rapid adoption of new and advanced R&D tools by leading pharmaceutical companies and Contract Research Organizations (CROs) for drug discovery and development. These companies are increasingly focusing on joint ventures and research collaborations, which are further expected to boost market growth in the region. For instance, in August 2022, Atomwise entered into a strategic multi-target research collaboration with Sanofi for AI-powered drug discovery. The collaboration will focus on leveraging the company's AtomNet platform for up to five drug targets as part of their computational discovery and research efforts.
Drug Discovery Informatics Market Report Scope
Industry Developments and Future Opportunities:
As per company press releases, a few initiatives taken by key players operating in the global drug discovery informatics market are listed below:
- In January 2024, Evotec partnered with the Crohn's & Colitis Foundation to develop new treatments for inflammatory bowel disease (IBD). Under this partnership, both companies will use Evotec's comprehensive R&D platform to advance drug discovery for two innovative drug targets that address fibrosis and impaired intestinal barrier function.
- In November 2023, Certara introduced Simcyp Biopharmaceutics software, which aims to increase the efficiency of formulation development for new and generic drugs. The Simcyp Biopharmaceutics software is designed to assist biopharmaceutics, formulation, and scientists in quickly and cost-effectively formulating complex, novel, and generic small molecule medicines.
- In June 2022, Chemical.AI and Chemaxon announced a collaboration to integrate their scientific informatics software. Chemical.AI, a renowned Artificial Intelligence (AI) firm, announced a strategic partnership with Chemaxon, a leading chemical and biological software development company. The collaboration allows end users to access Chemaxon's Design Hub and Chemical.AI's ChemAIRS as an option.
- In April 2022, Certara, Inc. and Chemaxon entered a strategic partnership to modernize pharmaceutical research. The partnership provides interconnectivity between their scientific informatics workflows. Certara's Scientific Informatics software will seamlessly connect with Chemaxon's Design Hub, providing users with analytics and compound design. This co-development builds on integrations between Certara and Chemaxon products, such as the JChem chemistry cartridge, MarvinSketch, and JChem for Office.
Competitive Landscape and Key Companies:
Certara; Infosys Ltd.; Collaborative Drug Discovery, Inc.; Jubliant Biosys; Curia Global, Inc.; Chemaxon Ltd; Charles River Laboratories; Agilent Technologies, Inc.; Illumina, Inc; Boehringer Ingelheim International GmbH; and Evotec are among the prominent companies profiled in drug discovery informatics market report. These companies focus on new technologies, existing product advancements, and geographic expansions to meet the growing consumer demand worldwide.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Workflow, Service, Solution, End User, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Drug discovery informatics is a field that integrates computational and information sciences with chemistry and biology. It uses various computational tools, algorithms, and databases to study and interpret vast volumes of biological and chemical data.
The drug discovery informatics majorly consists of the players, including Certara; Infosys Ltd.; Collaborative Drug Discovery, Inc.; Jubliant Biosys; Curia Global, Inc.; Chemaxon Ltd; Charles River Laboratories; Agilent Technologies, Inc.; Illumina, Inc; Boehringer Ingelheim International GmbH; and Evotec.
Key factors driving the drug discovery informatics growth are the increasing investments in the R&D of new drug molecules by pharmaceutical companies and the growing adoption of computational and information tools for drug discovery and development.
The drug discovery informatics market, by workflow, is bifurcated into discovery informatics and drug development. The discovery informatics segment held a larger market share in 2023.
The drug discovery informatics was valued at US$ 3.073billion in 2023.
The drug discovery informatics is expected to be valued at US$ 8.17 billion in 2031.
1. Introduction
1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness Analysis
3. Research Methodology
4. Drug Discovery Informatics Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
4.3.1 List of Vendors in the Value Chain
5. Drug Discovery Informatics Market - Key Market Dynamics
5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints
6. Drug Discovery Informatics Market - Global Market Analysis
6.1 Drug Discovery Informatics - Global Market Overview
6.2 Drug Discovery Informatics - Global Market and Forecast to 2031
7. Drug Discovery Informatics Market – Revenue Analysis (USD Million) – By Workflow, 2021-2031
7.1 Overview
7.2 Discovery Informatics
7.3 Drug Development
8. Drug Discovery Informatics Market – Revenue Analysis (USD Million) – By Service, 2021-2031
8.1 Overview
8.2 Sequence Analysis Platform
8.3 Molecular Modeling
8.4 Clinical Trial Data Management
8.5 Docking
8.6 Others
9. Drug Discovery Informatics Market – Revenue Analysis (USD Million) – By Solution, 2021-2031
9.1 Overview
9.2 Software
9.3 Services
10. Drug Discovery Informatics Market – Revenue Analysis (USD Million) – By End User, 2021-2031
10.1 Overview
10.2 Pharmaceutical and Biotechnology Companies
10.3 Contract Research Organizations
10.4 Others
11. Drug Discovery Informatics Market - Revenue Analysis (USD Million), 2021-2031 – Geographical Analysis
11.1 North America
11.1.1 North America Drug Discovery Informatics Market Overview
11.1.2 North America Drug Discovery Informatics Market Revenue and Forecasts to 2031
11.1.3 North America Drug Discovery Informatics Market Revenue and Forecasts and Analysis - By Workflow
11.1.4 North America Drug Discovery Informatics Market Revenue and Forecasts and Analysis - By Service
11.1.5 North America Drug Discovery Informatics Market Revenue and Forecasts and Analysis - By Solution
11.1.6 North America Drug Discovery Informatics Market Revenue and Forecasts and Analysis - By End User
11.1.7 North America Drug Discovery Informatics Market Revenue and Forecasts and Analysis - By Countries
11.1.7.1 United States Drug Discovery Informatics Market
11.1.7.1.1 United States Drug Discovery Informatics Market, by Workflow
11.1.7.1.2 United States Drug Discovery Informatics Market, by Service
11.1.7.1.3 United States Drug Discovery Informatics Market, by Solution
11.1.7.1.4 United States Drug Discovery Informatics Market, by End User
11.1.7.2 Canada Drug Discovery Informatics Market
11.1.7.2.1 Canada Drug Discovery Informatics Market, by Workflow
11.1.7.2.2 Canada Drug Discovery Informatics Market, by Service
11.1.7.2.3 Canada Drug Discovery Informatics Market, by Solution
11.1.7.2.4 Canada Drug Discovery Informatics Market, by End User
11.1.7.3 Mexico Drug Discovery Informatics Market
11.1.7.3.1 Mexico Drug Discovery Informatics Market, by Workflow
11.1.7.3.2 Mexico Drug Discovery Informatics Market, by Service
11.1.7.3.3 Mexico Drug Discovery Informatics Market, by Solution
11.1.7.3.4 Mexico Drug Discovery Informatics Market, by End User
Note - Similar analysis would be provided for below mentioned regions/countries
11.2 Europe
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 Spain
11.2.5 United Kingdom
11.2.6 Rest of Europe
11.3 Asia-Pacific
11.3.1 Australia
11.3.2 China
11.3.3 India
11.3.4 Japan
11.3.5 South Korea
11.3.6 Rest of Asia-Pacific
11.4 Middle East and Africa
11.4.1 South Africa
11.4.2 Saudi Arabia
11.4.3 U.A.E
11.4.4 Rest of Middle East and Africa
11.5 South and Central America
11.5.1 Brazil
11.5.2 Argentina
11.5.3 Rest of South and Central America
12. Industry Landscape
12.1 Mergers and Acquisitions
12.2 Agreements, Collaborations, Joint Ventures
12.3 New Product Launches
12.4 Expansions and Other Strategic Developments
13. Competitive Landscape
13.1 Heat Map Analysis by Key Players
13.2 Company Positioning and Concentration
14. Drug Discovery Informatics Market - Key Company Profiles
14.1 Certara
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
Note - Similar information would be provided for below list of companies
14.2 Infosys Ltd
14.3 Collaborative Drug Discovery, Inc
14.4 Jubliant Biosys
14.5 Curia Global, Inc
14.6 Chemaxon Ltd
14.7 Charles River Laboratories
14.8 Agilent Technologies, Inc
14.9 Illumina, Inc
14.10 Boehringer Ingelheim International GmbH
14.11 Evotec
15. Appendix
15.1 Glossary
15.2 About The Insight Partners
15.3 Market Intelligence Cloud
The List of Companies - Drug Discovery Informatics Market
- Certara
- Infosys Ltd.
- Collaborative Drug Discovery, Inc.
- Jubliant Biosys
- Curia Global, Inc.
- Chemaxon Ltd
- Charles River Laboratories
- Agilent Technologies, Inc.
- Illumina, Inc
- Boehringer Ingelheim International GmbH
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For